Abstract 601: Nicotinic Acid Prevents and Restores Steatohepatitis Together with Amelioration of Postprandial Dyslipidemia.

Background and aims: ICR mouse neonatally administered with monosodium glutamate (MSG) shows obesity, insulin resistance, and is a murine model of steatohepatitis. We analysed the effect of nicotinic acid (niacin), an antilipidemic drug and also a potent lipolysis inhibitor. Methods: Neonatal ICR mice were subcutaneously injected with 2 mg/g of MSG or saline at 5 consecutive days after birth and fed a normal chow. Niacin was administered by dietary supplementation (0.5% w/w) since 5 week-old. After 12 weeks, mice were sacrificed and tissue samples were collected. Niacin was also administered to 12 week-old mice already having steatosis for 12 weeks. Results: After 12 weeks of treatment of niacin, MSG-treated mice showed less weight of body (21.5%, p Conclusion: Niacin prevented and ameliorated steatohepatitis together with amelioration of postprandial dyslipidemia at least partially due to inhibition of NEFA influx into the liver, although niacin impaired postprandial insulin response.